Annals of Clinical and Experimental NeurologyAnnals of Clinical and Experimental NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-2533Eco-Vector33510.17816/psaic335Original articlesОригинальные статьиUnknownResults of the study of avonex efficiency in multiple sclerosisРезультаты исследования эффективности авонекса при рассеянном склерозеPeresedovaA. V.ПереседоваA. В.
Russian Federation
neuro_inf@neurology.ruStoidaN. I.СтойдаН. И.
Russian Federation
neuro_inf@neurology.ruAskarovaLola Sh.АскароваЛола Шавкатовна
Russian Federation
neuro_inf@neurology.ruZakharovaMaria N.ЗахароваМария Николаевна
Russian Federation
neuro_inf@neurology.ruAdarchevaL. S.АдарчеваЛ. С.
Russian Federation
neuro_inf@neurology.ruNiyazbekovaA. S.НиязбековаA. С.
Russian Federation
neuro_inf@neurology.ruTrifonovaOlga V.ТрифоноваОльга Васильевна
Russian Federation
neuro_inf@neurology.ruRebrovaO. Yu.РеброваO. Ю.
Russian Federation
neuro_inf@neurology.ruZavalishinI. A.ЗавалишинИ. A.
Russian Federation
neuro_inf@neurology.ruResearch Center of NeurologyФГБНУ «Научный центр неврологии»Research Center of Neurology, Russian Academy of Medical Sciences,ФГБНУ «Научный центр неврологии»Research Center of Neurology, Russian Academy of Medical SciencesФГБНУ «Научный центр неврологии»1309201043202403022017Copyright ©; 2010, Peresedova A.V., Stoida N.I., Askarova L.S., Zakharova M.N., Adarcheva L.S., Niyazbekova A.S., Trifonova O.V., Rebrova O.Y., Zavalishin I.A.Copyright ©; 2010, Peresedova A.V., Stoida N.I., Askarova L.S., Zakharova M.N., Adarcheva L.S., Niyazbekova A.S., Trifonova O.V., Rebrova O.Y., Zavalishin I.A.2010Peresedova A.V., Stoida N.I., Askarova L.S., Zakharova M.N., Adarcheva L.S., Niyazbekova A.S., Trifonova O.V., Rebrova O.Y., Zavalishin I.A.Peresedova A.V., Stoida N.I., Askarova L.S., Zakharova M.N., Adarcheva L.S., Niyazbekova A.S., Trifonova O.V., Rebrova O.Y., Zavalishin I.A.https://creativecommons.org/licenses/by/4.0https://annaly-nevrologii.com/pathID/article/view/335

Results of the two-year treatment with avonex of 34 patients with relapsing remitting multiple sclerosis are summarized. This study provides evidence for the significant decrease in activity of the pathological process in patients treated with avonex, which is confirmed by the reduction of the relapse rate and the increase of theproportion of patients remaining exacerbation-free. The decrease of the EDSS score has also been shown. In general, avonex was tolerated well in patients under study.

В статье обобщены результаты двухлетнего лечения авонексом 34 больных ремиттирующим рассеянным склерозом. На фоне терапии показано достоверное уменьшение активности патологического процесса, характеризующееся снижением количества обострений и увеличением числа пациентов без экзацербаций. Выявлено уменьшение степени инвалидизации пациентов по шкале EDSS. В целом, отмечена хорошая переносимость лечения препаратом.

multiple sclerosistherapyavonexрассеянный склерозтерапияавонексBermel R.A., Weinstock-Guttman B., Bourdette D. et al. Intramuscular interferon beta-1a therapy in patients with relapsingremitting multiple sclerosis: a 15-year follow-up study. Mult. Scler. Online First, published on February 18, 2010.Betaseron Efficacy Yielding Outcomes of New Dose (BEYOND). Press Release, Bayer Healthcare AG, October 29, 2007.Boster A., Racke M.K. Pharmacotherapy of multiple sclerosis: the PROOF trial. Expert Opin. Pharmacother. 2009; 10: 1235–1237.Clanet M., Radue E.W., Kappos L. et al. A randomized, doubleblind dose comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59: 1507–1517.Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol. Sci. 2008; 29 (Suppl. 2): 253–255.Freedman S.M. Dose response to interferon therapy in multiple sclerosis: an evaluation of the evidence. Curr. Med. Res. Opin. 2009; 25: 547–557.PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon -1a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498–1504.Reynolds M.W., Stephen R., Seaman C., Rajagopalan K. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr. Med. Res. Opin. 2010; 26: 663–674.The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicentral, randomized double bind, placebo-controlled trial. Neurology 1993; 43: 655–661.Zidanov R., Locatelli L., Cookfair D. et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult. Scler. 2007; 13: 490–501.Zidanov R., Munschauer F.E., Ramanathan M. et al. Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS. Drugs Today 2008; 44: 601–613.